Current Pharmacological Treatments for COVID-19: A Review of Clinical Evidence
by Cristina Scavone / Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
Available on 1 platform
Sign in to view source links and access this dataset
Description
Cristina Scavone from Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli authored a review paper summarizing pharmacological treatments for COVID-19. The paper describes drugs' mechanisms of action, safety profiles, and drug-drug interactions, focusing on antivirals and immunomodulators. It reports data from clinical trials and real-world settings for drugs like lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, and tocilizumab.
Use Cases
Reviewing clinical evidence for repurposed drugs based on the described pharmacological properties.
Analyzing safety and efficacy profiles of antivirals and immunomodulators based on the reported clinical trial data.
Studying drug-drug interactions for COVID-19 treatment regimens based on the described pharmacological information.
Strengths
Focuses on specific drugs like lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, and tocilizumab.
Reports data from clinical trials and real-world settings where available.
Limitations
Row count is unknown, which may limit suitability assessment.
Column-level documentation is absent; field semantics must be inferred after download.
Last update date is unknown; freshness unverified.
Provenance
Source
Cristina Scavone, Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
Collection Method
Literature review and synthesis of clinical evidence.
Time Range
Period following the COVID-19 outbreak starting December 2019.
Geography
Global, referencing studies registered worldwide.
License is Open Access (green). The input describes a review paper, not a structured dataset; the actual data content and format are unspecified.